Neurogene Balance Sheet
NASDAQ: NGNEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neurogene financial position
At the end of fiscal 2025, Neurogene reported total assets of $288.6 million, down 14.0% from a year earlier against total liabilities of $23.7 million. Shareholders' equity stood at $264.9 million, or 91.8% of assets. The company held $103.8 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 16.56, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Neurogene balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 103.84M | 136.59M | 148.21M | 82.02M | 142.47M | 192.56M | 143.09M | 76.93M | 52.03M | 32.30M |
| Short-Term Investments | 165.17M | 175.82M | 48.95M | 0 | 0 | — | — | — | 56.05M | 70.76M |
| Total Current Assets | 271.77M | 315.92M | 200.35M | 84.72M | 143.99M | 194.52M | 143.60M | 77.17M | 108.83M | 103.48M |
| Property, Plant & Equipment | 12.79M | 15.42M | 17.17M | 20.11M | 6.45M | 3.57M | 2.06M | 400.00K | 905.00K | 849.00K |
| Intangible Assets | — | — | — | 0 | 128.00K | 347.00K | 567.00K | — | — | — |
| Total Assets | 288.60M | 335.73M | 222.57M | 109.27M | 163.26M | 210.52M | 147.02M | 77.62M | 110.33M | 154.38M |
| Accounts Payable | 1.95M | 1.34M | 2.60M | 625.00K | 526.00K | 1.32M | 1.60M | 702.00K | 6.02M | 6.86M |
| Total Current Liabilities | 16.41M | 15.16M | 22.97M | 6.65M | 8.64M | 7.89M | 4.74M | 4.63M | 10.96M | 9.52M |
| Total Liabilities | 23.72M | 25.36M | 36.55M | 10.64M | 20.40M | 19.30M | 5.34M | 4.95M | 11.44M | 9.72M |
| Shareholders' Equity | 264.89M | 310.38M | 186.02M | -145.74M | -91.88M | 191.22M | 141.69M | 72.67M | 98.89M | 144.66M |
| Retained Earnings | -352.65M | -262.30M | -187.15M | -150.84M | -393.50M | -332.81M | -299.53M | -230.09M | -198.50M | -148.28M |
| Net Cash (Debt) | 269.01M | 312.40M | 197.16M | 82.02M | 142.47M | 192.56M | 143.09M | 76.93M | 108.08M | 103.06M |
| Shares Outstanding | 15.49M | 14.85M | 12.82M | 0 | 42.46M | 42.20M | 38.00M | 23.54M | 23.47M | 23.42M |
This table shows 10 annual periods of Neurogene's balance sheet, from FY 2025 back to FY 2016, across 13 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow NGNE's reporting calendar. What is a balance sheet?